DiamiR Biosciences Partners with JADBio to Utilize Machine Learning in Assay Development

10th July, 2023

DiamiR Biosciences, a developer of innovative non-invasive blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into an agreement with JADBio to utilize its Automated Machine Learning (AutoML) Platform and Services for development of predictive models based on DiamiR's microRNA panels and other factors for risk assessment in Alzheimer's disease and Rett syndrome.

Image Source : Public Domain

Alidad Mireskandari, Ph.D., DiamiR's CEO commented that "applying Machine Learning capabilities to our microRNA platform is a key step towards validation of our diagnostic tests. We are excited about partnering with JADBio, a leader in Automated Machine Learning in life sciences, to develop sophisticated, proprietary ML based testing algorithms to further our development efforts."

"We are thrilled to be partnering with DiamiR," said JADBio's CEO, Pavlos Charonyktakis, "as we are confident that our state-of-the-art ML platform and services will prove instrumental in DiamiR's efforts to efficiently validate their biomarker panels and develop highly accurate diagnostic tests."